^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

DRD2 antagonist

1d
Decoding the immunopharmacological basis of ECT-induced clozapine level elevation: Insights from a Quantitative Systems Pharmacology model. (PubMed, Eur J Pharmacol)
The QSP model provides a robust, mechanistically plausible explanation for the observed ECT-clozapine interaction, identifying the inflammatory cascade as the critical driver of impaired clozapine metabolism. The model serves as a powerful tool for simulating patient risk and provides a quantitative foundation for developing personalized, model-informed dosing strategies to enhance the safety of this crucial concomitant therapy.
Journal
|
IL6 (Interleukin 6) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2) • CRP (C-reactive protein) • DRD2 (Dopamine Receptor D2)
2d
Carbergoline for Antipsychotic Induced Hyperprolactinemia. (clinicaltrials.gov)
P4, N=146, Not yet recruiting, Zealand University Hospital
New P4 trial • Head-to-Head
2d
Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma. (PubMed, Neuro Oncol)
B7-H3 CAR T cells combined with ONC206 is a feasible and efficacious multi-agent approach against multiple DIPG models.
Preclinical • Journal
|
CD276 (CD276 Molecule) • IL2 (Interleukin 2) • GZMB (Granzyme B) • IFNL1 (Interferon Lambda 1)
|
JZP3507
3d
Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov)
P2, N=180, Active, not recruiting, Central Institute of Mental Health, Mannheim | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Dec 2027
Enrollment closed • Trial completion date • Trial primary completion date
|
olanzapine
7d
New trial
7d
New trial
|
chlorpromazine
7d
New trial
7d
New trial
7d
New trial
|
celecoxib oral • olanzapine
8d
Dopamine Agonist Therapy Induced Fatal Pneumocephalus in Giant Prolactinoma. (PubMed, JCEM Case Rep)
Dopamine agonist (DA) cabergoline (0.25 mg twice weekly) was initiated, and serum prolactin levels reached 3941 ng/mL (SI: 171.3 nmol/L) after 2 doses...Our case and review of 7 published cases of DA-induced pneumocephalus highlights male predominance, median tumor size of 5.5 cm (range, 4-9.5 cm), and onset within 1 to 12 weeks of initiation of DA therapy. Hence, for giant prolactinomas after DA initiation, it is essential to recognize the symptom complex associated with this rare life-threatening complication, pneumocephalus, and offer emergency surgical intervention.
Journal
|
PRL (Prolactin)